

6. A process of aiding regression and palliation of lung cancer which comprises the systemic administration to human or animal subjects hosting lung cancer of an effective antineoplastic amount of a member selected from the group consisting of 2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole and the therapeutically active acid addition salts thereof in a pharmaceutical carrier.

7. A process of aiding regression and palliation of lung cancer which comprises the systemic administration to a human hosting lung cancer of from about 1 to about 5 mg/kg body weight of the host of a member selected from the group consisting of 2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole and the therapeutically active acid addition salts thereof.

8. A process of aiding regression and palliation of malignant melanoma which comprises the systemic administration to human or animal subjects hosting malignant melanoma of an effective antineoplastic amount of a member selected from the group consisting of 2,3,5,6-tetrahydro-6-phenylimidazo-[2,1-b]thiazole and the therapeutically active acid addition salts thereof in a pharmaceutical carrier.

9. A process of aiding regression and palliation of malignant melanoma which comprises the systemic administration to a human hosting malignant melanoma of from about 1 to about 5 mg/kg body weight of the host member selected from the group consisting of 2,3,5,6-tetrahydro-6-phenylimidazo-[2,1-b]thiazole and the therapeutically active acid addition salts thereof.

10. A process of aiding regression and palliation of colorectal cancer which comprises the systemic administration to human or animal subject hosting colorectal cancer of an effective antineoplastic amount of a member selected from the group consisting of 2,3,5,6-tetrahydro-6-phenylimidazo-[2,1-b]thiazole and the therapeutically active acid addition salts thereof in a pharmaceutical carrier.

26-

8,9 11. A process of aiding regression and palliation of colorectal cancer which comprises the systemic administration to a human hosting colorectal cancer of from about 1 to about 5 mg/kg body weight of the host of a member selected from the group consisting of 2,3,5,6-tetrahydro-6-phenylimidazo-[2,1-b]thiazole and the therapeutically active acid addition salts thereof.

8,9 12. A process of aiding regression and palliation of multiple myeloma which comprises the systemic administration to human or animal subjects hosting multiple myeloma of an effective antineoplastic amount of a member selected from the group consisting of 2,3,5,6-tetrahydro-6-phenylimidazo-[2,1-b]thiazole and the therapeutically active acid addition salts thereof in a pharmaceutical carrier.

β<sup>1</sup> 13. A process of aiding regression and palliation of multiple myeloma which comprises the systemic administration to a human hosting multiple myeloma of from about 1 to about 5 mg/kg body weight of the host of a member selected from the group consisting of 2,3,5,6-tetrahydro-6-phenylimidazo-[2,1-b]thiazole and the therapeutically active acid addition salts thereof.

8,9 14. A process of aiding regression and palliation of head and neck cancer which comprises the systemic administration to human or animal subjects hosting head and neck cancer of an effective antineoplastic amount of a member selected from the group consisting of 2,3,5,6-tetrahydro-6-phenylimidazo-[2,1-b]thiazole and the therapeutically active acid addition salts thereof in a pharmaceutical carrier.

8,9 15. A process of aiding regression and palliation of head and neck cancer which comprises the systemic administration to a human hosting head and neck cancer of from about 1 to about 5 mg/kg body weight of the host of a member selected from the group consisting of 2,3,5,6-tetrahydro-6-phenylimidazo-[2,1-b]thiazole and the therapeutically active acid addition salts thereof.

37

16. A process of aiding regression and palliation of bladder cancer which comprises the systemic administration to human or animal subjects hosting bladder cancer of an effective antineoplastic amount of a member selected from the group consisting of 2,3,5,6-tetrahydro-6-phenylimidazo-[2,1-b]thiazole and the therapeutically active acid addition salts thereof in a pharmaceutical carrier.

17. A process of aiding regression and palliation of bladder cancer which comprises the systemic administration to a human hosting bladder cancer of from about 1 to about 5 mg/kg body weight of the host of a member selected from the group consisting of 2,3,5,6-tetrahydro-6-phenylimidazo-[2,1-b]thiazole and the therapeutically active acid addition salts thereof.

18. A process of aiding regression and palliation of gastric cancer which comprises the systemic administration to human or animal subjects hosting gastric cancer of an effective antineoplastic amount of a member selected from the group consisting of 2,3,5,6-tetrahydro-6-phenylimidazo-[2,1-b]thiazole and the therapeutically active acid addition salts thereof in a pharmaceutical carrier.

19. A process of aiding regression and palliation of gastric cancer which comprises the systemic administration to a human hosting gastric cancer of from about 1 to about 5 mg/kg body weight of the host of a member selected from the group consisting of 2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole and the therapeutically active acid addition salts thereof.

#### REMARKS

The subject continuation application is being filed to present claims of narrower scope and to make of record a summary of the best available evidence to date supporting the subject claims.